Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer

Yuichi Hisamatsu, Eriko Tokunaga, Nami Yamashita, Sayuri Akiyoshi, Satoko Okada, Yuichiro Nakashima, Shinichi Aishima, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. Assessing indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)- positive/human epidermal receptor 2 (HER2)-negative breast cancer remains a challenge for oncologists. In this study, we evaluated whether forkhead-box protein A1 (FOXA1) expression was a prognostic and predictive marker for HR-positive breast cancer. Methods. FOXA1 expression was analyzed immunohistochemically in 239 primary breast cancers. Associations between FOXA1 expression and clinicopathological characteristics and prognosis were evaluated. Results. FOXA1 expression was positively correlated with estrogen receptor (ER) (P<0.0001) and progesterone receptor (PR) expression (P = 0.0011), and inversely correlated with nuclear grade (P = 0.0048) and Ki67 index (P = 0.0112). High FOXA1 was associated with longer recurrence-free survival (RFS) in all cases (P<0.0001) and in ER-positive cases (P\0.0001), but not in ERnegative cases. In addition, FOXA1 expression was associated with good prognosis, regardless of the Ki67 index, in HR-positive cases. FOXA1 was an independent prognostic factor on multivariate analysis in all cases and in ERpositive cases. Among HR-positive/HER2-negative cases with high FOXA1 expression, there was no difference in RFS between those given hormone therapy (HT) alone and those given CT plus HT. Conclusions. In HR-positive breast cancer, FOXA1 expression was significantly associated with good prognosis. FOXA1 expression may be a useful marker for HRpositive/ HER2-negative breast cancer to identify patients with good prognosis who may not require CT.

Original languageEnglish
Pages (from-to)1145-1152
Number of pages8
JournalAnnals of Surgical Oncology
Volume19
Issue number4
DOIs
Publication statusPublished - Apr 1 2012

Fingerprint

Hormones
Breast Neoplasms
Estrogen Receptors
Hepatocyte Nuclear Factor 3-alpha
Recurrence
Drug Therapy
Survival
Progesterone Receptors
Adjuvant Chemotherapy
Multivariate Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. / Hisamatsu, Yuichi; Tokunaga, Eriko; Yamashita, Nami; Akiyoshi, Sayuri; Okada, Satoko; Nakashima, Yuichiro; Aishima, Shinichi; Morita, Masaru; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Annals of Surgical Oncology, Vol. 19, No. 4, 01.04.2012, p. 1145-1152.

Research output: Contribution to journalArticle

Hisamatsu, Y, Tokunaga, E, Yamashita, N, Akiyoshi, S, Okada, S, Nakashima, Y, Aishima, S, Morita, M, Kakeji, Y & Maehara, Y 2012, 'Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer', Annals of Surgical Oncology, vol. 19, no. 4, pp. 1145-1152. https://doi.org/10.1245/s10434-011-2094-4
Hisamatsu, Yuichi ; Tokunaga, Eriko ; Yamashita, Nami ; Akiyoshi, Sayuri ; Okada, Satoko ; Nakashima, Yuichiro ; Aishima, Shinichi ; Morita, Masaru ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 4. pp. 1145-1152.
@article{10e9a9c9f6f74d4ba5c839af6d0e13ef,
title = "Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer",
abstract = "Background. Assessing indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)- positive/human epidermal receptor 2 (HER2)-negative breast cancer remains a challenge for oncologists. In this study, we evaluated whether forkhead-box protein A1 (FOXA1) expression was a prognostic and predictive marker for HR-positive breast cancer. Methods. FOXA1 expression was analyzed immunohistochemically in 239 primary breast cancers. Associations between FOXA1 expression and clinicopathological characteristics and prognosis were evaluated. Results. FOXA1 expression was positively correlated with estrogen receptor (ER) (P<0.0001) and progesterone receptor (PR) expression (P = 0.0011), and inversely correlated with nuclear grade (P = 0.0048) and Ki67 index (P = 0.0112). High FOXA1 was associated with longer recurrence-free survival (RFS) in all cases (P<0.0001) and in ER-positive cases (P\0.0001), but not in ERnegative cases. In addition, FOXA1 expression was associated with good prognosis, regardless of the Ki67 index, in HR-positive cases. FOXA1 was an independent prognostic factor on multivariate analysis in all cases and in ERpositive cases. Among HR-positive/HER2-negative cases with high FOXA1 expression, there was no difference in RFS between those given hormone therapy (HT) alone and those given CT plus HT. Conclusions. In HR-positive breast cancer, FOXA1 expression was significantly associated with good prognosis. FOXA1 expression may be a useful marker for HRpositive/ HER2-negative breast cancer to identify patients with good prognosis who may not require CT.",
author = "Yuichi Hisamatsu and Eriko Tokunaga and Nami Yamashita and Sayuri Akiyoshi and Satoko Okada and Yuichiro Nakashima and Shinichi Aishima and Masaru Morita and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2012",
month = "4",
day = "1",
doi = "10.1245/s10434-011-2094-4",
language = "English",
volume = "19",
pages = "1145--1152",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer

AU - Hisamatsu, Yuichi

AU - Tokunaga, Eriko

AU - Yamashita, Nami

AU - Akiyoshi, Sayuri

AU - Okada, Satoko

AU - Nakashima, Yuichiro

AU - Aishima, Shinichi

AU - Morita, Masaru

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background. Assessing indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)- positive/human epidermal receptor 2 (HER2)-negative breast cancer remains a challenge for oncologists. In this study, we evaluated whether forkhead-box protein A1 (FOXA1) expression was a prognostic and predictive marker for HR-positive breast cancer. Methods. FOXA1 expression was analyzed immunohistochemically in 239 primary breast cancers. Associations between FOXA1 expression and clinicopathological characteristics and prognosis were evaluated. Results. FOXA1 expression was positively correlated with estrogen receptor (ER) (P<0.0001) and progesterone receptor (PR) expression (P = 0.0011), and inversely correlated with nuclear grade (P = 0.0048) and Ki67 index (P = 0.0112). High FOXA1 was associated with longer recurrence-free survival (RFS) in all cases (P<0.0001) and in ER-positive cases (P\0.0001), but not in ERnegative cases. In addition, FOXA1 expression was associated with good prognosis, regardless of the Ki67 index, in HR-positive cases. FOXA1 was an independent prognostic factor on multivariate analysis in all cases and in ERpositive cases. Among HR-positive/HER2-negative cases with high FOXA1 expression, there was no difference in RFS between those given hormone therapy (HT) alone and those given CT plus HT. Conclusions. In HR-positive breast cancer, FOXA1 expression was significantly associated with good prognosis. FOXA1 expression may be a useful marker for HRpositive/ HER2-negative breast cancer to identify patients with good prognosis who may not require CT.

AB - Background. Assessing indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)- positive/human epidermal receptor 2 (HER2)-negative breast cancer remains a challenge for oncologists. In this study, we evaluated whether forkhead-box protein A1 (FOXA1) expression was a prognostic and predictive marker for HR-positive breast cancer. Methods. FOXA1 expression was analyzed immunohistochemically in 239 primary breast cancers. Associations between FOXA1 expression and clinicopathological characteristics and prognosis were evaluated. Results. FOXA1 expression was positively correlated with estrogen receptor (ER) (P<0.0001) and progesterone receptor (PR) expression (P = 0.0011), and inversely correlated with nuclear grade (P = 0.0048) and Ki67 index (P = 0.0112). High FOXA1 was associated with longer recurrence-free survival (RFS) in all cases (P<0.0001) and in ER-positive cases (P\0.0001), but not in ERnegative cases. In addition, FOXA1 expression was associated with good prognosis, regardless of the Ki67 index, in HR-positive cases. FOXA1 was an independent prognostic factor on multivariate analysis in all cases and in ERpositive cases. Among HR-positive/HER2-negative cases with high FOXA1 expression, there was no difference in RFS between those given hormone therapy (HT) alone and those given CT plus HT. Conclusions. In HR-positive breast cancer, FOXA1 expression was significantly associated with good prognosis. FOXA1 expression may be a useful marker for HRpositive/ HER2-negative breast cancer to identify patients with good prognosis who may not require CT.

UR - http://www.scopus.com/inward/record.url?scp=84862505855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862505855&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-2094-4

DO - 10.1245/s10434-011-2094-4

M3 - Article

C2 - 21984487

AN - SCOPUS:84862505855

VL - 19

SP - 1145

EP - 1152

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -